Education
About Us
Working with TipRanks
Follow Us
Mesoblast Limited (MEOBF)
OTHER OTC:MEOBF
MEOBF Stock Chart & Stats
$1.55
$0.00(0.00%)
At close: 4:00 PM EST
$1.55
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.96 - $2.68
Previous CloseN/A
Volume20.00
Average Volume (3M)69.00
Market Cap
$1.98B
Enterprise Value$2.09B
Total Cash (Recent Filing)$161.16M
Total Debt (Recent Filing)$128.16M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Sep 02, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding1,290,302,200
10 Day Avg. Volume100
30 Day Avg. Volume69
Financial Highlights & Ratios
PEG Ratio-27.18
Price to Book (P/B)2.09
Price to Sales (P/S)72.48
P/FCF Ratio-24.59
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue121.68
Enterprise Value/Gross Profit-58.36
Enterprise Value/Ebitda-35.97
Forecast
1Y Price Target
$2.70Price Target Upside74.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$90.31M
Bulls Say, Bears Say
Bulls Say
Commercial Launch TractionEarly adoption across 32 U.S. transplant centers and broad insurance coverage creates durable commercial distribution and payer access. This scale and payer reach support recurring hospital demand, faster uptake, and predictable revenue growth as Ryoncil expands to cover a larger share of pediatric transplants.
High Gross Margin And Cash ReservesA 90% gross margin implies very strong unit economics for product sales, enabling high cash conversion as volumes grow. Coupled with $162M cash on hand, Mesoblast has a meaningful runway to support commercialization, regulatory work and pivotal trials without immediate dilution, improving strategic optionality.
Multiple Large-market Pipeline OpportunitiesHaving label expansion pathways (adult GvHD, IBD) plus a second-generation program in a >$10B chronic low back pain market provides several durable growth levers. Multiple later-stage assets reduce single-product binary risk and increase long-term revenue potential across distinct therapeutic markets.
Bears Say
Persistent Net Losses And Negative ROEDespite revenue growth, the company is not yet profitable and shows a negative ROE, signaling it isn't generating returns on shareholders' equity. Prolonged losses require continued funding, may dilute existing holders, and test management's ability to convert clinical success into sustainable profitability.
Operating Cash Flow Remains NegativeNegative operating cash flow indicates core operations and commercialization are not yet cash-generative. While free cash flow rose, that may reflect timing or nonrecurring items; sustained negative operating cash flow raises risk to runway and could necessitate external financing during continued commercial expansion.
Rising Operating Expenses And Non-cash ChargesRapidly increased SG&A from commercial build raises fixed cost base, pressuring margins until sales scale. Large non-cash revaluation and warrant losses introduce volatility to reported results and reflect contingent obligations tied to approvals and share moves, complicating forecasts and capital allocation planning.
Mesoblast Limited News
MEOBF FAQ
What was Mesoblast Limited’s price range in the past 12 months?
Mesoblast Limited lowest stock price was $0.96 and its highest was $2.68 in the past 12 months.
What is Mesoblast Limited’s market cap?
Mesoblast Limited’s market cap is $1.98B.
When is Mesoblast Limited’s upcoming earnings report date?
Mesoblast Limited’s upcoming earnings report date is Sep 02, 2026 which is in 178 days.
How were Mesoblast Limited’s earnings last quarter?
Mesoblast Limited released its earnings results on Feb 27, 2026. The company reported -$0.031 earnings per share for the quarter, missing the consensus estimate of -$0.007 by -$0.024.
Is Mesoblast Limited overvalued?
According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued.
Does Mesoblast Limited pay dividends?
Mesoblast Limited does not currently pay dividends.
What is Mesoblast Limited’s EPS estimate?
Mesoblast Limited’s EPS estimate is >-0.01.
How many shares outstanding does Mesoblast Limited have?
Mesoblast Limited has 1,290,302,200 shares outstanding.
What happened to Mesoblast Limited’s price movement after its last earnings report?
Mesoblast Limited reported an EPS of -$0.031 in its last earnings report, missing expectations of -$0.007. Following the earnings report the stock price went down -2.516%.
Which hedge fund is a major shareholder of Mesoblast Limited?
Currently, no hedge funds are holding shares in MEOBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.70 (74.29% Upside)
$2.70 (74.29% Upside)
Blogger Sentiment
Bullish
MEOBF Sentiment 96%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.82%
12-Months-Change
Fundamentals
Return on Equity
-18.95%
Trailing 12-Months
Asset Growth
17.27%
Trailing 12-Months
Company Description
Mesoblast Limited
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
MEOBF Company Deck
MEOBF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive trajectory for Mesoblast, driven by the successful commercial launch of Ryoncil and significant revenue growth. Despite increased expenses and some regulatory challenges, the company shows robust market potential and financial health.View all MEOBF earnings summariesMEOBF Stock 12 Month Forecast
Average Price Target
$2.70
▲(74.29% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Neuren Pharmaceuticals Limited
―
Orthocell Ltd
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Ownership Overview
21.29% Insiders
2.27% Mutual Funds
0.01% Other Institutional Investors
73.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---